HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Misra, U. K. Articles by Patel, R. Search for Related Content PubMed PubMed Citation Articles by Misra, U. K. Articles by Patel, R. Related Collections Status epilepticus All Epilepsy/Seizures Antiepileptic drugs

Sodium valproate vs phenytoin in status epilepticus: A pilot study

From the Department of Neurology, Sanjay Gandhi PGIMS, Lucknow, India.

Address correspondence and reprint requests to Dr Misra, Department of Neurology, Sanjay Gandhi PGIMS, Lucknow 226014, India; e-mail: drukmisra{at}rediffmail.com

Sixty-eight patients with convulsive status epilepticus (SE) were randomly assigned to two groups to study the efficacy of sodium valproate (VPA) and phenytoin (PHT). Seizures were aborted in 66% in the VPA group and 42% in the PHT group. As a second choice in refractory patients, VPA was effective in 79% and PHT was effective in 25%. The side effects in the two groups did not differ. Sodium valproate may be preferred in convulsive SE because of its higher efficacy.

Disclosure: The authors report no conflicts of interest.

Received July 26, 2005. Accepted in final form March 20, 2006.

This article has been cited by other articles:

				E. Trinka and J. Dobesberger Review: New treatment options in status epilepticus: a critical review on intravenous levetiracetam Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 79 - 91. [Abstract] [PDF]

				F. Rosenow and S. Knake Review: Recent and future advances in the treatment of status epilepticus Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 25 - 32. [Abstract] [PDF]

				M. J Jackson Should we accept the status quo? Time for new trials in status epilepticus J. Neurol. Neurosurg. Psychiatry, May 1, 2008; 79(5): 490 - 490. [Full Text] [PDF]

				K. El Karoui, M. Le Quintrec, E. Dekeyser, A. Servais, A. Hummel, F. Fadel, and F. Fakhouri Posterior reversible encephalopathy syndrome in systemic lupus erythematosus Nephrol. Dial. Transplant., February 1, 2008; 23(2): 757 - 763. [Full Text] [PDF]

				S. Beyenburg, C. Back, N. Diederich, M. Lewis, and M. Reuber Is valproate encephalopathy under-recognised in older people? A case series Age Ageing, May 1, 2007; 36(3): 344 - 346. [Abstract] [Full Text] [PDF]

				T. A. Glauser Designing Practical Evidence-Based Treatment Plans for Children With Prolonged Seizures and Status Epilepticus J Child Neurol, May 1, 2007; 22(5_suppl): 38S - 46S. [Abstract] [PDF]

				A. O. Rossetti, U .K. Misra, J . Kalita, and R . Patel Sodium valproate vs phenytoin in status epilepticus: A pilot study Neurology, February 27, 2007; 68(9): 709 - 709. [Full Text] [PDF]

Correspondence: